Jeroen Bloemhard
President, Healthcare & Water Technologies at DD
Executive
About Jeroen Bloemhard
Jeroen Bloemhard, 57, is President of Healthcare & Water Technologies at DuPont, appointed effective November 1, 2025; he previously led DuPont Water Solutions and held senior commercial roles at Celanese and Dow Corning, with a career focus at the intersection of material science and application engineering . Under his segment remit, DuPont has highlighted operating EBITDA margins around 30% and mid-single-digit organic growth, with water business revenue characterized by ~70% recurring replacement-cycle demand, and ongoing portfolio expansion via bolt-ons and TAM broadening (e.g., RO acquisition and APAC manufacturing localization) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| DuPont de Nemours, Inc. | President, Healthcare & Water Technologies | 2025–present | Appointed post-electronics separation to lead growth and execution; segment positioned for ~30% operating EBITDA margin and mid-single-digit growth . |
| DuPont | VP & GM, Water Solutions | 2024–2025 | Led global Water Solutions; emphasized end-to-end offerings and recurring revenue nature (~70% replacement cycles) . |
| Celanese | Chief Commercial Officer, Mobility & Materials; later Global Commercial VP – Industrial/Medical/Consumer | 2022–2023 | Senior commercial leadership in multi-industrial markets . |
| DuPont | Global VP & GM, Performance Resins; later Chief Commercial Officer across Engineering Polymers and Performance Resins | 2018–2019 | Portfolio-wide commercial leadership across engineering polymers/resins . |
| Dow Corning | Specialty growth businesses leader | pre-2018 | Built innovation-led advantages combining materials and application engineering . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Celanese | Senior commercial executive (CCO; Global Commercial VP) | 2022–2023 | External perspective on complex global markets; commercial excellence . |
Fixed Compensation
- DuPont’s November 2025 8-K appointing Bloemhard disclosed biographical details and confirmed no related-party transactions or appointment arrangements; it did not disclose his base salary or bonus terms .
- Company-wide governance: no single-trigger change-in-control agreements or excise tax gross-ups; pay mix heavily performance-based; strong ownership requirements (CEO 6x, others 3x) .
Performance Compensation
Short-Term Incentive Program (STIP) Design
| Component | Metric | Weighting | Notes |
|---|---|---|---|
| Corporate | Corporate Adjusted EPS | 50% | Quarterly measured; 85% threshold, 115% max . |
| Business Segment | Segment Organic Revenue | 20% | Quarterly measured; 90% threshold, 110% max . |
| Business Segment | Segment Operating EBITDA | 15% | Quarterly measured; 80% threshold, 115% max . |
| Business Segment | Segment Adjusted Free Cash Flow | 15% | Quarterly measured; 80% threshold, 120% max . |
| Modifier | Sustainability | ± up to 10% | Applied to annual payout; committee retained reallocation feature . |
2024 STIP Final Payout Factors (as reported in 2025 Proxy)
| Group | Final Payout Factor (%) |
|---|---|
| Electronics & Industrial | 112.8% |
| Water & Protection | 110.8% |
| Corporate Aligned | 111.9% |
Long-Term Incentives (LTI) Design
| Vehicle | Weight in LTI | Metric/Term | Payout Range | Vesting |
|---|---|---|---|---|
| PSUs | 60% | Adjusted ROIC (50%); Adjusted Corporate Net Income (50%); Relative TSR modifier vs S&P 500 | 0%–200% | 3-year performance period . |
| RSUs | 40% | Time-based | N/A | 3-year incremental vesting . |
Context: Committee approved a 120.84% payout for the 2021 PSU cycle ending Dec 31, 2023, illustrating multi-year pay-for-performance alignment .
Equity Ownership & Alignment
- Stock ownership guidelines: executives required to hold DuPont shares at a multiple of base salary; retention ratio requires 75% of net shares from vesting/exercise until guidelines met (RSUs and stock units count; options/PSUs excluded) .
- Multiples and actuals (as of Dec 31, 2024 for NEOs):
Role Target Multiple Actual Multiple Executive Chairman 6x 18.2x CEO 6x 8.8x Other NEOs (avg) 3x 6.2x - Anti-hedging and anti-pledging: directors and officers prohibited from hedging and pledging company securities .
Note: The November 2025 8-K confirms Bloemhard’s appointment but does not disclose his personal share ownership; watch for Form 3/4 filings following officer appointment for specifics .
Employment Terms
| Provision | Terms |
|---|---|
| Senior Executive Severance Plan (SESP) | Double-trigger required for CIC benefits (CIC + qualifying termination within 24 months) . |
| Severance multiples | 1.5x base salary + target bonus for involuntary termination without cause (non-CIC); 2.0x for CIC double-trigger; plus target/actual year bonus, benefits continuation, outplacement . |
| Restrictive covenants | 12-month non-compete and non-solicitation; non-disparagement/confidentiality; release required . |
| Clawback policy | Robust recoupment policy updated in 2023 to comply with NYSE/SEC rules, and extends to misconduct beyond minimum requirements . |
| Equity treatment on termination | RSUs automatically vest on death or involuntary termination; PSUs prorated over original performance period; options remain exercisable for defined post-termination windows . |
The November 2025 8-K did not include a specific employment or offer letter for Bloemhard; SESP and equity plan terms above reflect company-wide policies that typically govern executive officers .
Performance & Track Record
- Segment financial profile: Healthcare & Water expected ~30% operating EBITDA margin and mid-single-digit growth; Healthcare business size cited at ~$1.7B with leadership positions in medical devices, biopharma single-use systems, sterile packaging and PPE .
- Water recurring revenue: ~70% of annual revenue from replacement cycles of existing installations, underpinning cash flow resilience .
- Strategic execution: DuPont announced RO manufacturing expansion in China via Sinochem (Ningbo) Memtech acquisition to localize production and serve APAC demand for FilmTec elements; aligns with footprint diversification and supply chain risk mitigation .
- China exposure management: Commentary indicates reducing relative dependence on China in water over time, with growth in Middle East desalination and PAC microelectronics .
Investment Implications
- Alignment and incentives: Bloemhard’s segment metrics (EBITDA margin ~30%, mid-single-digit growth) and company STIP/LTI structure (EPS, segment EBITDA/FCF; ROIC/net income with TSR modifier) suggest strong pay-for-performance linkage and emphasize capital discipline and profitability .
- Retention risk: Absent disclosed personal compensation terms, retention is supported by recurring revenue profile in water and expansion opportunities in healthcare; watch for future off-cycle LTI alignment similar to CEO/CFO adjustments in 2024, and any disclosed severance/change-in-control protections under SESP .
- Trading signals: Monitor forthcoming Forms 3/4 for Bloemhard’s beneficial ownership and any RSU/PSU vesting or sales; anti-hedging/pledging policies reduce misalignment risk, while sustainability and payout modifiers may affect annual bonus realizations .
- Strategic catalysts: Execution on RO footprint expansion, healthcare CDMO capabilities, and end-market mix shift away from China reliance could underpin segment revenue durability and margin stability, supportive of long-term incentive outcomes .